Zacks: Analysts Expect Agenus Inc. (AGEN) to Announce -$0.37 EPS
Equities analysts forecast that Agenus Inc. (NASDAQ:AGEN) will post earnings per share of ($0.37) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Agenus’ earnings. Agenus posted earnings of ($0.30) per share in the same quarter last year, which indicates a negative year over year growth rate of 23.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 8th.
According to Zacks, analysts expect that Agenus will report full-year earnings of ($1.19) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.12). For the next year, analysts forecast that the business will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.40) to ($1.37). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Agenus.
Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.37). The business had revenue of $3.40 million for the quarter, compared to the consensus estimate of $5.91 million. The company’s quarterly revenue was down 24.4% compared to the same quarter last year.
In other news, CEO Garo H. Armen bought 100,000 shares of the stock in a transaction on Monday, October 30th. The shares were purchased at an average cost of $3.55 per share, for a total transaction of $355,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.60% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in shares of Agenus in the third quarter valued at $134,000. OxFORD Asset Management LLP bought a new stake in shares of Agenus in the second quarter valued at $141,000. Voya Investment Management LLC raised its stake in shares of Agenus by 18.5% in the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 6,381 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Agenus during the 2nd quarter valued at $207,000. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Agenus by 12.2% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock valued at $211,000 after purchasing an additional 6,101 shares during the period. Hedge funds and other institutional investors own 37.90% of the company’s stock.
Shares of Agenus (NASDAQ AGEN) opened at $3.97 on Friday. Agenus has a fifty-two week low of $3.20 and a fifty-two week high of $5.45. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of -2.39.
ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Agenus Inc. (AGEN) to Announce -$0.37 EPS” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/03/zacks-analysts-expect-agenus-inc-agen-to-announce-0-37-eps.html.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.